Clinical trial
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In…
NCT00191672 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191672 |
|---|---|
| Title | A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer |
| Official title | A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine, Paclitaxel, Docetaxel |
| Enrollment | 120 |
| Start date | Dec 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: